Company / Operating Income per Share
Denali Therapeutics Inc. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$3.85
FY2025
5-year range
-$3.85 / $0.51
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
#157 of 201
Health Care
What the data says
Denali Therapeutics Inc.'s operating income per share of $-3.85 is lower than 78% of companies in the Health Care sector (FY2025). Operating Income per Share has declined for 3 consecutive years, from $0.51 in FY2022 to $-3.85 in FY2025.
Based on SEC 10-K filings.
-3.85 in FY2025.
Declined from $-1.45 to $-3.85 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 201This company -$3.85 Sector average -$3.23
▼
-19.1% below sector average
Key checks
Key Insights
- Denali Therapeutics Inc.'s operating income per share has declined for 3 consecutive years.
- In FY2025, operating income per share decreased 9.3% year-over-year.
- Ranks #157 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$3.85 | -9.3% |
| FY2024 | -$3.52 | -143.4% |
| FY2023 | -$1.45 | -382.1% |
| FY2022 | $0.51 | +129.0% |
| FY2021 | -$1.77 | -266.9% |
| FY2020 | -$0.48 | +49.4% |
| FY2019 | -$0.95 | +4.7% |
| FY2018 | -$1.00 | +83.4% |
| FY2017 | -$6.02 | +55.7% |
| FY2016 | -$13.61 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026